Editorial: Genetics of Familial Hypercholesterolemia: New Insight by Vuorio, A et al.
EDITORIAL
published: 06 May 2021
doi: 10.3389/fgene.2021.669373
Frontiers in Genetics | www.frontiersin.org 1 May 2021 | Volume 12 | Article 669373
Edited and reviewed by:
Jordi Pérez-Tur,






This article was submitted to
Genetics of Common and Rare
Diseases,
a section of the journal
Frontiers in Genetics
Received: 18 February 2021
Accepted: 07 April 2021
Published: 06 May 2021
Citation:
Vuorio A, Ramaswami U and
Holven KB (2021) Editorial: Genetics
of Familial Hypercholesterolemia: New
Insight. Front. Genet. 12:669373.
doi: 10.3389/fgene.2021.669373
Editorial: Genetics of Familial
Hypercholesterolemia: New Insight
Alpo Vuorio 1,2*, Uma Ramaswami 3,4 and Kirsten B. Holven 5,6
1Mehiläinen Airport Health Centre, Vantaa, Finland, 2Department of Forensic Medicine, University of Helsinki, Helsinki,
Finland, 3 Lysosomal Disorders Unit, Royal Free London National Health Service Foundation Trust, London, United Kingdom,
4Genetics and Genomics Department, University College London, London, United Kingdom, 5Department of Nutrition,
Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway, 6Norwegian National Advisory Unit on Familial
Hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital,
Oslo, Norway
Keywords: familial hypercholesterolemia, mutations, atherosclerosis, LDL cholesterol, statins, PCSK9 inhibitors
Editorial on the Research Topic
Genetics of Familial Hypercholesterolemia: New Insight
The Research Topic “Genetics Familial Hypercholesterolemia: New Insight” attracted over
100 authors from 16 countries to submit manuscripts on topical genetic research in familial
hypercholesterolemia (FH). Encouragingly, over fifty percent of the manuscripts were from low-
and middle-income countries researchers from very different backgrounds. This achieved our goal
of bringing together researchers from worldwide. It also reaffirmed conclusions from Vrablik et al.
review article: “The coordinated international efforts should increase the chances of achieving the
principal goal—to identify, diagnose and provide treatment for all FH patients early enough.” The
strength of this review topic was the submission of manuscripts from researchers at different stages
of their research portfolio. For example, Dušková et al. analyzed in detail pathogenic variants in
the low-density lipoprotein gene and their effects on protein localization, function and expression
of genes associate endoplasmic reticulum representing advanced molecular biology approaches.
At the same time Vasilyev et al. were working with basic molecular biology questions and they
concluded that “major achievements in the genetic investigation of the molecular features of FH in
Russia are yet to come.”
Unfortunately, FH still remains vastly underdiagnosed disease. As an example, is the study by
Ramaswami et al. (2019) that was carried out in UK pediatric population. This study demonstrated
that <550 children with a confirmed diagnosis of heterozygous FH (HeFH) were being managed
in the health care system. This was despite an estimated prevalence of 50,000 children under
the age of 18 years with HeFH in the UK based on a population prevalence of 1 in 250. Once
diagnosed, it is essential to enable long-term follow-up of these patients and collating longitudinal
data on the management and safety of disease modifying therapies such as statins and newer
emerging treatments. This would be possible with both national and international HeFH registries.
These registries could also potentially help genotype-phenotype correlations related to different
HeFH pathogenic mutations in the LDLR, APOB, or PCSK9 genes. This could also apply to genes
associated to HeFH diagnosis, and which are differentially expressed compared to non-FH controls
Udhaya Kumar et al..
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Truong et al. described the Vietnam Familial Registry
(VINAFH) and reported that the VINAFH registry have had
a favorable effect on government legislative policies. This
highlighted the importance of registries in managing and
providing evidence based supportive information for HeFH
populations in low- and middle-income countries, and indeed
we believe that national and international registries are a
key part of management and follow up of both adults
and children with HeFH globally. The advantage of HeFH
registries would apply especially to large Asian countries
where the HeFH diagnosis rates are low Huang and Charng
and where HeFH awareness is also still low amongst health
care professionals.
In addition to clinically suspected cases of HeFH who
are mutation-negative for LDLR, APOB, or PCSK9 mutations,
there are patients with severe hypercholesterolemia who have
an accumulation of common small-effect LDL cholesterol
raising alleles (Talmud et al., 2013). These patients are
defined as “polygenic hypercholesterolemia.” Jarauta et al.
highlighted the importance of newer genetic methods to
diagnose “polygenic hypercholesterolemia” early and to ensure
initiation of a lipid lowering therapy in a timely manner.
However, the genetic criterion for the diagnosis of “polygenic
hypercholesterolemia” remains a challenge. Genetic testing for
monogenic HeFH could potentially also help identify “polygenic
hypercholesterolemia” but this option is not utilized effectively
Kamar et al..
Recently, Futema et al. (2021) demonstrated that both
children and adults with HeFH caused by pathogenic LDLR
mutation have a higher LDL cholesterol concentration compared
to HeFH caused by APOBmutation.
Healthy diet and lifestyle and early statin treatment are
cornerstones in HeFH treatment (Vuorio et al., 2019; Rodríguez-
Borjabad et al., 2021). Statin treatment has been shown to be
safe and effective in children with HeFH (Humphries et al., 2018;
Vuorio et al., 2019). However, many children with HeFH are
not on appropriate lipid-lowering treatments (Ramaswami et al.,
2020), including our European patients. It has been speculated
that the widespread use of genetic testing has been crucial for
the increased statin use in Norway, especially in young children
with HeFH aged 10–19 years compared to their Scandinavian
neighbors with less prevalent genetic testing (Svendsen et al.,
2021). Despite this, the prevalence of patients with HeFH among
patients with premature acute myocardial infarction (AMI)
remains significantly higher compared to the general population
in Norway (Bogsrud et al., 2020). The most likely explanation is
the increased lifelong cholesterol burden prior to their AMI, and
an increased LDL cholesterol concentration at the time of AMI.
Similar results were also confirmed byMoradi et al. in Iran. It has
been also shown that mortality and the risk of recurrent AMI is
increased in HeFH compared with non-FH controls (Svendsen
et al., 2020). A poor prognosis after the first AMI in HeFH
patients was also confirmed in this Research Topic by Arnesen
et al..
PCSK9 inhibitors represent a relatively new class of
medication that targets the unique mechanism of action of
PCSK9 Guo et al.. The effectiveness and safety of PCSK9
inhibitor was shown recently in pediatric HeFH (Santos
et al., 2020). In this 24-week study, the mean LDL cholesterol
lowering was −44.5% and −6.2% in children with HeFH
on evolocumab, a PCSK9 inhibitor, and a control group,
respectively. Inclisiran (Hovingh et al., 2020) highlights the
effective use of such adjunctive therapies that potentially help
achieve appropriate target LDL cholesterol concentration
and better clinical outcomes. Oommen et al. described that
over half of the HeFH causing LDLR mutations resulted in
protein misfolding, defective transport and trafficking, with the
misfolded proteins being retained in the endoplasmic reticulum
(ER). The authors postulate drugs modulating proteostasis in the
ER as therapeutic alternatives for patients who have persistently
elevated LDL cholesterol despite optimization of conventional
lipid lowering therapies.
Homozygous form of FH (HoFH) is a rare disease with a
prevalence ∼1:200,000–30,000 (Sjouke et al., 2015). HoFH is a
serious disease due to very aggressive atherosclerosis progression.
Without early interventions, HoFH causes AMI in childhood
(Vallejo-Vaz et al., 2015). In the current Research Topic,
Marusic et al. showed that HoFH patients represent a clinically
heterogenous group. In some cases, the HoFH phenotype may
overlap with HeFH, and hence genetic testing is paramount.
The authors highlight the lack of therapeutic options for HoFH
patients in less developed countries. Mlinaric et al. reported an
interesting case of liver transplantation (LT) in a HoFH child
with progressive atherosclerosis despite early LDL-apheresis. The
authors suggest LT as a feasible option especially in HoFH
unresponsive to lipid lowering therapies and/or LDL-apheresis.
The authors also suggest the benefits of an international registry
for HoFH and LT. The International Registry on Lipoprotein
Apheresis in Children with HoFH could serve as an example
(Luirink et al., 2020).
The most recent challenge related to FH is the COVID-19
pandemic (Vuorio et al., 2021a). It can be estimated that with
a HeFH prevalence of 1 in 250, ∼440,000 HeFH patients may
have had SARS-Cov-2 infection by February 2021. In severely ill
COVID-19 patients, HeFH could potentially be overrepresented
due to endothelial dysfunction and atherosclerotic cardiovascular
disease as risk factors (Vuorio et al., 2020). A lifelong elevated
LDL cholesterol concentration is often associated with an
increased lipoprotein(a) Lp(a), with endothelial dysfunction
starting in childhood. In a meta-analysis carried among
hospitalized COVID-19 patients, AMI was present in 3.3% (95%
CI 0.3–8.5) of the cases (Kunutsor and Laukkanen, 2020). A
meta-analysis of COVID-19 studies revealed that statin use
decreases not only the mortality but also the severity of SARS-
Cov-2 infection significantly (OR 0.51, 95% CI 0.41–0.64)
(Onorato et al., 2021). Therefore, among patients with HeFH, an
effective lowering of LDL cholesterol concentration is essential to
improve endothelial dysfunction (Iqbal et al., 2020; Vuorio and
Kovanen, 2020) and potentially reduce COVID-19 risk. PSCSK9
inhibitors could also be considered as an adjunctive therapy
to effectively lowering both LDL cholesterol concentration and
Lp(a), with also potential antiviral properties (Iqbal et al., 2020;
Vuorio and Kovanen, 2021). An effective lowering of LDL
cholesterol concentration, especially in older patients with HeFH
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is important to mitigate the higher risk of becoming critically
ill with COVID-19 (Vuorio et al., 2021b). Currently, there is
a great need to collect comprehensive epidemiologic data with
the aid of international collaboration among the centers on the
clinical course and outcomes of FH patients who have contracted
COVID-19 infection.
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